Matthew Rossman
Concepts (299)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vasodilation | 23 | 2025 | 520 | 3.600 |
Why?
| | Endothelium, Vascular | 21 | 2026 | 949 | 3.420 |
Why?
| | Aging | 23 | 2026 | 1938 | 2.990 |
Why?
| | Vascular Stiffness | 14 | 2026 | 485 | 2.870 |
Why?
| | Antioxidants | 7 | 2026 | 546 | 2.720 |
Why?
| | Exercise | 24 | 2025 | 2183 | 2.380 |
Why?
| | Brachial Artery | 9 | 2025 | 206 | 2.340 |
Why?
| | Mitochondria | 8 | 2026 | 984 | 2.230 |
Why?
| | Oxidative Stress | 18 | 2026 | 1338 | 2.120 |
Why?
| | Leg | 16 | 2025 | 240 | 2.100 |
Why?
| | Postmenopause | 3 | 2026 | 390 | 1.720 |
Why?
| | Nitric Oxide | 15 | 2025 | 894 | 1.610 |
Why?
| | Cellular Senescence | 8 | 2026 | 223 | 1.480 |
Why?
| | Mitochondria, Muscle | 6 | 2026 | 120 | 1.370 |
Why?
| | Muscle Fatigue | 5 | 2017 | 97 | 1.210 |
Why?
| | Vascular Diseases | 5 | 2023 | 252 | 1.200 |
Why?
| | Blood Vessels | 3 | 2020 | 167 | 1.110 |
Why?
| | Muscle, Skeletal | 18 | 2026 | 1788 | 1.100 |
Why?
| | Pulmonary Ventilation | 2 | 2022 | 82 | 1.080 |
Why?
| | Aorta | 6 | 2026 | 427 | 1.070 |
Why?
| | Endothelial Cells | 10 | 2026 | 864 | 1.050 |
Why?
| | Cardiovascular Diseases | 8 | 2026 | 2172 | 1.050 |
Why?
| | Femoral Artery | 10 | 2025 | 190 | 0.980 |
Why?
| | Reactive Oxygen Species | 11 | 2025 | 601 | 0.940 |
Why?
| | Ubiquinone | 1 | 2026 | 35 | 0.940 |
Why?
| | Exercise Tolerance | 7 | 2026 | 282 | 0.930 |
Why?
| | Regional Blood Flow | 15 | 2025 | 513 | 0.920 |
Why?
| | Flavonols | 4 | 2026 | 26 | 0.880 |
Why?
| | Organophosphorus Compounds | 1 | 2026 | 84 | 0.880 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 5 | 2017 | 919 | 0.870 |
Why?
| | Ascorbic Acid | 3 | 2021 | 171 | 0.860 |
Why?
| | Movement | 8 | 2022 | 295 | 0.850 |
Why?
| | Doxorubicin | 4 | 2026 | 398 | 0.780 |
Why?
| | NAD | 1 | 2023 | 82 | 0.760 |
Why?
| | Dietary Supplements | 7 | 2026 | 575 | 0.730 |
Why?
| | Aged | 37 | 2026 | 25955 | 0.720 |
Why?
| | Quadriceps Muscle | 7 | 2021 | 118 | 0.710 |
Why?
| | Citrulline | 1 | 2022 | 46 | 0.710 |
Why?
| | Pulse Wave Analysis | 8 | 2026 | 266 | 0.680 |
Why?
| | Healthy Lifestyle | 2 | 2018 | 37 | 0.680 |
Why?
| | Flavonoids | 3 | 2026 | 86 | 0.670 |
Why?
| | Kidney Diseases | 1 | 2025 | 427 | 0.670 |
Why?
| | Sodium Nitrite | 1 | 2021 | 39 | 0.650 |
Why?
| | Sympathetic Nervous System | 5 | 2026 | 180 | 0.640 |
Why?
| | Bronchi | 1 | 2022 | 263 | 0.620 |
Why?
| | Physical Endurance | 3 | 2025 | 274 | 0.610 |
Why?
| | Anti-Asthmatic Agents | 1 | 2022 | 253 | 0.590 |
Why?
| | Stroke Volume | 4 | 2019 | 650 | 0.570 |
Why?
| | Humans | 72 | 2026 | 144667 | 0.540 |
Why?
| | Hand Strength | 5 | 2026 | 144 | 0.520 |
Why?
| | Heating | 1 | 2017 | 18 | 0.520 |
Why?
| | Cross-Over Studies | 4 | 2026 | 605 | 0.510 |
Why?
| | Kidney | 1 | 2025 | 1495 | 0.510 |
Why?
| | Male | 52 | 2026 | 72431 | 0.500 |
Why?
| | Mice, Inbred C57BL | 11 | 2026 | 5967 | 0.500 |
Why?
| | Asthma | 2 | 2022 | 1774 | 0.490 |
Why?
| | Middle Aged | 25 | 2026 | 35971 | 0.480 |
Why?
| | Muscle Contraction | 7 | 2021 | 430 | 0.480 |
Why?
| | Blood Pressure | 8 | 2026 | 1766 | 0.440 |
Why?
| | Female | 36 | 2026 | 78304 | 0.430 |
Why?
| | Fatigue | 2 | 2014 | 363 | 0.430 |
Why?
| | Arteries | 5 | 2024 | 258 | 0.430 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2025 | 139 | 0.420 |
Why?
| | Young Adult | 23 | 2025 | 14122 | 0.420 |
Why?
| | Hyperemia | 5 | 2022 | 49 | 0.420 |
Why?
| | Heart | 1 | 2018 | 626 | 0.410 |
Why?
| | Vasoconstriction | 6 | 2022 | 216 | 0.410 |
Why?
| | Thioctic Acid | 1 | 2013 | 12 | 0.390 |
Why?
| | Mice | 17 | 2026 | 18261 | 0.390 |
Why?
| | Vitamin E | 1 | 2013 | 123 | 0.380 |
Why?
| | Nitrates | 3 | 2022 | 100 | 0.370 |
Why?
| | Smoking Water Pipes | 2 | 2023 | 9 | 0.370 |
Why?
| | Water Pipe Smoking | 2 | 2023 | 9 | 0.370 |
Why?
| | Animals | 22 | 2026 | 37948 | 0.370 |
Why?
| | Knee | 1 | 2012 | 71 | 0.350 |
Why?
| | Oxygen Consumption | 8 | 2025 | 717 | 0.350 |
Why?
| | Age Factors | 6 | 2025 | 3329 | 0.340 |
Why?
| | Adult | 26 | 2026 | 40489 | 0.340 |
Why?
| | Blood Flow Velocity | 6 | 2019 | 419 | 0.330 |
Why?
| | Resistance Training | 2 | 2023 | 185 | 0.320 |
Why?
| | Diet, Western | 2 | 2021 | 86 | 0.320 |
Why?
| | Healthy Volunteers | 4 | 2021 | 215 | 0.320 |
Why?
| | Aniline Compounds | 3 | 2025 | 121 | 0.320 |
Why?
| | Dementia | 2 | 2025 | 319 | 0.310 |
Why?
| | Exercise Test | 3 | 2022 | 626 | 0.310 |
Why?
| | Posture | 5 | 2016 | 197 | 0.280 |
Why?
| | Electromyography | 4 | 2014 | 416 | 0.270 |
Why?
| | Atherosclerosis | 3 | 2018 | 409 | 0.270 |
Why?
| | Caloric Restriction | 2 | 2020 | 126 | 0.260 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2025 | 657 | 0.260 |
Why?
| | Physical Conditioning, Animal | 2 | 2021 | 241 | 0.250 |
Why?
| | Inflammation | 6 | 2024 | 2870 | 0.250 |
Why?
| | Case-Control Studies | 6 | 2026 | 3603 | 0.240 |
Why?
| | Respiratory Function Tests | 2 | 2022 | 541 | 0.240 |
Why?
| | Biomarkers | 4 | 2025 | 4261 | 0.240 |
Why?
| | AIDS Vaccines | 1 | 2026 | 53 | 0.240 |
Why?
| | Chemokine CXCL12 | 1 | 2026 | 86 | 0.230 |
Why?
| | Motor Activity | 4 | 2024 | 723 | 0.230 |
Why?
| | Trastuzumab | 1 | 2026 | 117 | 0.220 |
Why?
| | Feedback, Physiological | 3 | 2014 | 81 | 0.220 |
Why?
| | Respiratory Muscles | 2 | 2023 | 37 | 0.220 |
Why?
| | Adjuvants, Immunologic | 1 | 2026 | 245 | 0.220 |
Why?
| | Premenopause | 1 | 2025 | 123 | 0.210 |
Why?
| | Spermidine | 1 | 2024 | 17 | 0.200 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2024 | 117 | 0.200 |
Why?
| | Nicotinamide Mononucleotide | 1 | 2023 | 9 | 0.200 |
Why?
| | Arterial Pressure | 5 | 2019 | 133 | 0.200 |
Why?
| | Endothelin-1 | 2 | 2016 | 181 | 0.190 |
Why?
| | Lipoproteins, LDL | 1 | 2023 | 119 | 0.190 |
Why?
| | Acetylcholine | 2 | 2023 | 208 | 0.190 |
Why?
| | Vaping | 1 | 2023 | 66 | 0.190 |
Why?
| | Sex Factors | 2 | 2025 | 2104 | 0.180 |
Why?
| | Inflammation Mediators | 1 | 2025 | 503 | 0.180 |
Why?
| | Social Class | 1 | 2024 | 265 | 0.180 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2023 | 108 | 0.180 |
Why?
| | Adolescent | 7 | 2023 | 22409 | 0.180 |
Why?
| | Administration, Oral | 2 | 2015 | 851 | 0.170 |
Why?
| | Hypertension | 2 | 2021 | 1262 | 0.170 |
Why?
| | Spirostans | 1 | 2021 | 4 | 0.170 |
Why?
| | Breathing Exercises | 1 | 2021 | 21 | 0.170 |
Why?
| | Glomerular Filtration Rate | 1 | 2025 | 764 | 0.170 |
Why?
| | Inhalation | 1 | 2021 | 29 | 0.170 |
Why?
| | Treatment Outcome | 4 | 2022 | 11735 | 0.170 |
Why?
| | Cardiovascular System | 3 | 2020 | 136 | 0.170 |
Why?
| | Hypotension | 1 | 2022 | 126 | 0.160 |
Why?
| | Cancer Survivors | 1 | 2026 | 330 | 0.160 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2021 | 106 | 0.160 |
Why?
| | Double-Blind Method | 3 | 2023 | 2033 | 0.160 |
Why?
| | HIV-1 | 1 | 2026 | 897 | 0.160 |
Why?
| | Cells, Cultured | 2 | 2025 | 4110 | 0.150 |
Why?
| | Pressoreceptors | 1 | 2019 | 19 | 0.150 |
Why?
| | Cardiovascular Abnormalities | 1 | 2019 | 15 | 0.150 |
Why?
| | Glucose Intolerance | 1 | 2021 | 142 | 0.150 |
Why?
| | Cognitive Dysfunction | 1 | 2025 | 464 | 0.150 |
Why?
| | Supine Position | 2 | 2016 | 37 | 0.150 |
Why?
| | Models, Animal | 1 | 2021 | 393 | 0.150 |
Why?
| | Receptors, Adrenergic, beta-1 | 1 | 2019 | 24 | 0.150 |
Why?
| | DNA Methylation | 1 | 2024 | 664 | 0.140 |
Why?
| | Coronary Circulation | 1 | 2019 | 134 | 0.140 |
Why?
| | Electron Transport | 1 | 2018 | 115 | 0.140 |
Why?
| | Athletes | 1 | 2022 | 421 | 0.140 |
Why?
| | Peptides, Cyclic | 3 | 2016 | 275 | 0.140 |
Why?
| | Carotid Arteries | 3 | 2025 | 207 | 0.140 |
Why?
| | Hemodynamics | 6 | 2023 | 1113 | 0.140 |
Why?
| | Fasting | 1 | 2020 | 275 | 0.140 |
Why?
| | Oncogene Protein p21(ras) | 1 | 2017 | 15 | 0.130 |
Why?
| | Energy Metabolism | 2 | 2021 | 927 | 0.130 |
Why?
| | Endothelin Receptor Antagonists | 2 | 2016 | 61 | 0.130 |
Why?
| | Heart Rate | 6 | 2023 | 853 | 0.130 |
Why?
| | Habits | 1 | 2017 | 52 | 0.130 |
Why?
| | Drug Monitoring | 1 | 2021 | 396 | 0.130 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2018 | 214 | 0.130 |
Why?
| | Coronary Vessels | 1 | 2019 | 246 | 0.130 |
Why?
| | Bicycling | 2 | 2021 | 116 | 0.130 |
Why?
| | Sulfonamides | 3 | 2025 | 579 | 0.120 |
Why?
| | Congresses as Topic | 1 | 2018 | 221 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2026 | 1961 | 0.120 |
Why?
| | Primary Prevention | 1 | 2018 | 217 | 0.120 |
Why?
| | Ventricular Function, Left | 1 | 2019 | 536 | 0.110 |
Why?
| | Cardiovascular Physiological Phenomena | 1 | 2015 | 48 | 0.110 |
Why?
| | Reflex | 1 | 2015 | 70 | 0.110 |
Why?
| | Cardiac Catheterization | 1 | 2019 | 557 | 0.110 |
Why?
| | Metabolomics | 1 | 2021 | 724 | 0.110 |
Why?
| | Reproducibility of Results | 3 | 2022 | 3414 | 0.110 |
Why?
| | Autonomic Nervous System | 1 | 2015 | 81 | 0.110 |
Why?
| | Life Style | 1 | 2017 | 481 | 0.110 |
Why?
| | Cell Respiration | 3 | 2021 | 105 | 0.110 |
Why?
| | Maximal Midexpiratory Flow Rate | 1 | 2014 | 5 | 0.110 |
Why?
| | Peak Expiratory Flow Rate | 1 | 2014 | 25 | 0.110 |
Why?
| | Muscle Strength | 3 | 2023 | 330 | 0.110 |
Why?
| | Pyramidal Tracts | 1 | 2014 | 30 | 0.100 |
Why?
| | omega-N-Methylarginine | 4 | 2015 | 29 | 0.100 |
Why?
| | Bronchoconstriction | 1 | 2014 | 29 | 0.100 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2014 | 26 | 0.100 |
Why?
| | Ultrasonography, Doppler | 4 | 2016 | 126 | 0.100 |
Why?
| | Receptors, Opioid, mu | 1 | 2014 | 66 | 0.100 |
Why?
| | Shear Strength | 1 | 2014 | 73 | 0.100 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2017 | 392 | 0.100 |
Why?
| | Extremities | 1 | 2014 | 140 | 0.100 |
Why?
| | Cardiac Output | 4 | 2015 | 179 | 0.100 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2017 | 532 | 0.100 |
Why?
| | Vital Capacity | 1 | 2014 | 290 | 0.100 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2016 | 441 | 0.100 |
Why?
| | Bronchodilator Agents | 1 | 2014 | 184 | 0.100 |
Why?
| | Electron Spin Resonance Spectroscopy | 1 | 2013 | 96 | 0.100 |
Why?
| | Breast Neoplasms | 1 | 2026 | 2365 | 0.100 |
Why?
| | Free Radicals | 1 | 2013 | 110 | 0.100 |
Why?
| | Forced Expiratory Volume | 1 | 2014 | 448 | 0.090 |
Why?
| | Recovery of Function | 1 | 2017 | 715 | 0.090 |
Why?
| | Coronary Artery Disease | 1 | 2019 | 743 | 0.090 |
Why?
| | Single-Blind Method | 1 | 2013 | 319 | 0.090 |
Why?
| | Fentanyl | 3 | 2021 | 127 | 0.090 |
Why?
| | Drug Combinations | 1 | 2013 | 393 | 0.090 |
Why?
| | Central Nervous System | 1 | 2014 | 279 | 0.090 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 779 | 0.080 |
Why?
| | Motor Neurons | 1 | 2013 | 235 | 0.080 |
Why?
| | HIV Infections | 1 | 2026 | 3148 | 0.080 |
Why?
| | Aged, 80 and over | 1 | 2023 | 8284 | 0.080 |
Why?
| | Spinal Cord | 1 | 2013 | 384 | 0.080 |
Why?
| | Knee Joint | 1 | 2014 | 426 | 0.080 |
Why?
| | Sepsis | 1 | 2016 | 643 | 0.070 |
Why?
| | Follow-Up Studies | 1 | 2018 | 5414 | 0.070 |
Why?
| | Biological Availability | 2 | 2021 | 143 | 0.070 |
Why?
| | Saponins | 1 | 2026 | 12 | 0.060 |
Why?
| | env Gene Products, Human Immunodeficiency Virus | 1 | 2026 | 15 | 0.060 |
Why?
| | Vaccinia virus | 1 | 2026 | 35 | 0.060 |
Why?
| | Immunization, Secondary | 1 | 2026 | 92 | 0.060 |
Why?
| | HIV Antibodies | 1 | 2026 | 61 | 0.060 |
Why?
| | Simian Immunodeficiency Virus | 1 | 2026 | 93 | 0.060 |
Why?
| | Macaca mulatta | 1 | 2026 | 186 | 0.060 |
Why?
| | Arterioles | 1 | 2025 | 52 | 0.060 |
Why?
| | Heart Failure | 1 | 2019 | 2324 | 0.060 |
Why?
| | Risk Factors | 3 | 2025 | 10796 | 0.050 |
Why?
| | Popliteal Artery | 1 | 2025 | 62 | 0.050 |
Why?
| | Genetic Vectors | 1 | 2026 | 334 | 0.050 |
Why?
| | Photoplethysmography | 2 | 2016 | 19 | 0.050 |
Why?
| | Immunity, Cellular | 1 | 2026 | 272 | 0.050 |
Why?
| | Liposomes | 1 | 2026 | 256 | 0.050 |
Why?
| | Fingers | 2 | 2016 | 107 | 0.050 |
Why?
| | Infusions, Intra-Arterial | 2 | 2015 | 61 | 0.050 |
Why?
| | Nitric Oxide Synthase | 2 | 2015 | 234 | 0.050 |
Why?
| | Elastic Modulus | 1 | 2024 | 121 | 0.050 |
Why?
| | Respiratory Therapy | 1 | 2023 | 25 | 0.050 |
Why?
| | Antibodies, Neutralizing | 1 | 2026 | 341 | 0.050 |
Why?
| | Nitric Oxide Synthase Type III | 2 | 2016 | 203 | 0.050 |
Why?
| | Lower Extremity | 2 | 2019 | 440 | 0.050 |
Why?
| | Forearm | 1 | 2023 | 140 | 0.050 |
Why?
| | Time Factors | 3 | 2021 | 7140 | 0.050 |
Why?
| | Hypercapnia | 1 | 2023 | 53 | 0.050 |
Why?
| | Muscles | 1 | 2023 | 332 | 0.050 |
Why?
| | Carbon Dioxide | 1 | 2023 | 239 | 0.040 |
Why?
| | Injections, Spinal | 1 | 2021 | 120 | 0.040 |
Why?
| | Blood Circulation | 1 | 2021 | 44 | 0.040 |
Why?
| | Nicotine | 1 | 2023 | 334 | 0.040 |
Why?
| | Neurons, Afferent | 1 | 2021 | 102 | 0.040 |
Why?
| | Random Allocation | 1 | 2021 | 366 | 0.040 |
Why?
| | Mouth | 1 | 2021 | 88 | 0.040 |
Why?
| | Cerebrovascular Circulation | 1 | 2023 | 289 | 0.040 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2026 | 915 | 0.040 |
Why?
| | Analgesics, Opioid | 2 | 2021 | 1142 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2024 | 305 | 0.040 |
Why?
| | Enzyme Inhibitors | 2 | 2015 | 820 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2024 | 770 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5870 | 0.040 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2026 | 1129 | 0.040 |
Why?
| | Infusions, Intralesional | 1 | 2019 | 1 | 0.040 |
Why?
| | Diet, High-Fat | 1 | 2021 | 261 | 0.040 |
Why?
| | Adrenergic Antagonists | 1 | 2019 | 5 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2024 | 669 | 0.040 |
Why?
| | Blood Pressure Determination | 1 | 2019 | 143 | 0.040 |
Why?
| | Risk Assessment | 2 | 2019 | 3729 | 0.040 |
Why?
| | Cytokines | 1 | 2026 | 2045 | 0.030 |
Why?
| | Retrospective Studies | 1 | 2016 | 17149 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2024 | 843 | 0.030 |
Why?
| | Reference Values | 1 | 2019 | 794 | 0.030 |
Why?
| | Oxidative Phosphorylation | 1 | 2018 | 209 | 0.030 |
Why?
| | Oxygen | 1 | 2022 | 984 | 0.030 |
Why?
| | ROC Curve | 1 | 2019 | 618 | 0.030 |
Why?
| | Homeostasis | 1 | 2021 | 639 | 0.030 |
Why?
| | Energy Intake | 1 | 2020 | 501 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2021 | 643 | 0.030 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2016 | 39 | 0.030 |
Why?
| | Electron Transport Complex IV | 1 | 2016 | 62 | 0.030 |
Why?
| | Program Development | 1 | 2018 | 368 | 0.030 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2016 | 71 | 0.030 |
Why?
| | Electron Transport Complex II | 1 | 2015 | 28 | 0.030 |
Why?
| | Electron Transport Complex I | 1 | 2015 | 42 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 1079 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2025 | 4539 | 0.030 |
Why?
| | Afferent Pathways | 1 | 2014 | 46 | 0.030 |
Why?
| | Evoked Potentials, Motor | 1 | 2014 | 50 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1886 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2117 | 0.020 |
Why?
| | Program Evaluation | 1 | 2018 | 941 | 0.020 |
Why?
| | Electromagnetic Fields | 1 | 2013 | 37 | 0.020 |
Why?
| | Amino Acids, Branched-Chain | 1 | 2013 | 39 | 0.020 |
Why?
| | Pulmonary Gas Exchange | 1 | 2013 | 116 | 0.020 |
Why?
| | Physical Exertion | 1 | 2014 | 205 | 0.020 |
Why?
| | Endothelin A Receptor Antagonists | 1 | 2012 | 24 | 0.020 |
Why?
| | Microbiota | 1 | 2021 | 782 | 0.020 |
Why?
| | Femoral Vein | 1 | 2012 | 38 | 0.020 |
Why?
| | Receptor, Endothelin A | 1 | 2012 | 60 | 0.020 |
Why?
| | Exercise Therapy | 1 | 2017 | 475 | 0.020 |
Why?
| | Tryptophan | 1 | 2013 | 175 | 0.020 |
Why?
| | Stress, Mechanical | 1 | 2014 | 494 | 0.020 |
Why?
| | Vascular Resistance | 1 | 2012 | 368 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2922 | 0.020 |
Why?
| | Catheterization, Peripheral | 1 | 2012 | 120 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2012 | 562 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4558 | 0.020 |
Why?
| | Lactic Acid | 1 | 2012 | 303 | 0.020 |
Why?
| | Ultrasonography | 1 | 2015 | 776 | 0.020 |
Why?
| | Lipids | 1 | 2014 | 706 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 4312 | 0.020 |
Why?
| | Cohort Studies | 1 | 2019 | 5957 | 0.020 |
Why?
| | Transcription Factors | 1 | 2016 | 1726 | 0.020 |
Why?
| | Obesity | 1 | 2021 | 3070 | 0.020 |
Why?
| | Prospective Studies | 1 | 2019 | 7994 | 0.020 |
Why?
| | Phenotype | 1 | 2014 | 3147 | 0.010 |
Why?
|
|
Rossman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|